223 related articles for article (PubMed ID: 18594787)
21. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Maxey DM; Ivy DD; Ogawa MT; Feinstein JA
Pediatr Cardiol; 2013 Oct; 34(7):1628-36. PubMed ID: 23532466
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.
Porta NF; Steinhorn RH
Clin Perinatol; 2012 Mar; 39(1):149-64. PubMed ID: 22341543
[TBL] [Abstract][Full Text] [Related]
23. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
24. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Porhownik NR; Al-Sharif H; Bshouty Z
Can Respir J; 2008; 15(8):427-30. PubMed ID: 19107243
[TBL] [Abstract][Full Text] [Related]
25. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil.
Caputo S; Furcolo G; Rabuano R; Basilicata AM; Pilla LM; De Simone A; Pasquariello B; Ciampi Q; Vetrano G; Villari B
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):704-6. PubMed ID: 19829144
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Gocho K; Sugino K; Ota H; Kusano E; Takai Y; Homma S
Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870
[TBL] [Abstract][Full Text] [Related]
27. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
28. The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia.
Wardle AJ; Wardle R; Luyt K; Tulloh R
Arch Dis Child; 2013 Aug; 98(8):613-7. PubMed ID: 23625986
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
30. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
[TBL] [Abstract][Full Text] [Related]
31. [Pulmonary arterial hypertension and systemic sclerosis].
Launay D; Humbert M; Hachulla E
Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
[TBL] [Abstract][Full Text] [Related]
32. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Humbert M
Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
[No Abstract] [Full Text] [Related]
33. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.
Gruenig E; Michelakis E; Vachiéry JL; Vizza CD; Meyer FJ; Doelberg M; Bach D; Dingemanse J; Galiè N
J Clin Pharmacol; 2009 Nov; 49(11):1343-52. PubMed ID: 19755415
[TBL] [Abstract][Full Text] [Related]
34. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R
Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
36. Sildenafil as a treatment for pulmonary hypertension.
Carroll WD; Dhillon R
Arch Dis Child; 2003 Sep; 88(9):827-8. PubMed ID: 12937112
[TBL] [Abstract][Full Text] [Related]
37. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia.
Kadmon G; Schiller O; Dagan T; Bruckheimer E; Birk E; Schonfeld T
Pediatr Pulmonol; 2017 Jan; 52(1):77-83. PubMed ID: 27333438
[TBL] [Abstract][Full Text] [Related]
39. Late clinical manifestations of mitral valve disease and severe pulmonary hypertension in a patient diagnosed with premature closure of foramen ovale during fetal life.
Iwamoto Y; Tamai A; Kawasaki H; Taketazu M; Senzaki H
World J Pediatr; 2011 May; 7(2):182-4. PubMed ID: 21574036
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report.
Mogollón MV; Lage E; Cabezón S; Hinojosa R; Ballesteros S; Aranda A; Sobrino JM; Ordóñez A
Transplant Proc; 2006 Oct; 38(8):2522-3. PubMed ID: 17097987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
